Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

May 11, 2018
Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-announces-fda-approval-gilenya-first-disease-modifying-therapy-pediatric-relapsing-multiple-sclerosis-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-announces-fda-approval-gilenya-first-disease-modifying-therapy-pediatric-relapsing-multiple-sclerosis-0